Adjustment of pharmacotherapy during the final days of life in home hospice care: a pilot retrospective study.

4区 医学 Q2 Nursing
Martina Novosadová, Stanislav Filip, Veronika Molnárová, Anna Michlová, Jana Hrubešová, Jakub Novosad
{"title":"Adjustment of pharmacotherapy during the final days of life in home hospice care: a pilot retrospective study.","authors":"Martina Novosadová, Stanislav Filip, Veronika Molnárová, Anna Michlová, Jana Hrubešová, Jakub Novosad","doi":"10.21037/apm-24-146","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Effective end-of-life care requires transitioning pharmacotherapy from chronic disease management to symptom relief. Patients in pre-terminal and terminal palliative care may be at risk of receiving potentially inappropriate drugs regarding indication, dosage, route of administration, and polypharmacy, which can increase the risk of deteriorating quality of life. However, data on this process in Home Hospice Care (HHC) is limited. This pilot retrospective study evaluated the pharmacotherapy of 50 patients during their final days under HHC, focusing on changes in treatment and preferred administration routes to optimize symptomatic care.</p><p><strong>Methods: </strong>Anonymised medical records data were analysed retrospectively to assess the shift from chronic disease pharmacotherapy to symptom and quality-of-life-focused treatment. Statistical methods were applied to identify trends in drug utilisation and administration routes.</p><p><strong>Results: </strong>The study group qualified the most common drugs associated with potential drug-related problems: antidepressants (26%), sedatives/hypnotics (32%), gastroprotection (34%), antihypertensives (46%), coanalgesics (50%), and analgesics (84%). On the final day, the mean was 2.64 systemic medication (standard deviation 1.27), with a minimum number of drugs and a maximum of 6. The most common symptom addressed was pain, which occurred in 28 patients in the group (56%). Therefore, terminal analgosedation was mapped in more detail when, at the end of life, 26 patients (52%) were terminally transferred to continuous medication administered subcutaneously. Continuous subcutaneous linear driver for analgosedation containing two components was used in 12 patients (46.2%) or three components in 14 patients (53.8%).</p><p><strong>Conclusions: </strong>This retrospective study highlights the importance of targeted pharmacotherapy adjustments in terminal care, including multidisciplinary HHC teams. Pharmacotherapy is simplified and targeted to prevalent symptoms, using the widely used subcutaneous drug administration.</p>","PeriodicalId":7956,"journal":{"name":"Annals of palliative medicine","volume":"14 2","pages":"136-145"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of palliative medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/apm-24-146","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Nursing","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Effective end-of-life care requires transitioning pharmacotherapy from chronic disease management to symptom relief. Patients in pre-terminal and terminal palliative care may be at risk of receiving potentially inappropriate drugs regarding indication, dosage, route of administration, and polypharmacy, which can increase the risk of deteriorating quality of life. However, data on this process in Home Hospice Care (HHC) is limited. This pilot retrospective study evaluated the pharmacotherapy of 50 patients during their final days under HHC, focusing on changes in treatment and preferred administration routes to optimize symptomatic care.

Methods: Anonymised medical records data were analysed retrospectively to assess the shift from chronic disease pharmacotherapy to symptom and quality-of-life-focused treatment. Statistical methods were applied to identify trends in drug utilisation and administration routes.

Results: The study group qualified the most common drugs associated with potential drug-related problems: antidepressants (26%), sedatives/hypnotics (32%), gastroprotection (34%), antihypertensives (46%), coanalgesics (50%), and analgesics (84%). On the final day, the mean was 2.64 systemic medication (standard deviation 1.27), with a minimum number of drugs and a maximum of 6. The most common symptom addressed was pain, which occurred in 28 patients in the group (56%). Therefore, terminal analgosedation was mapped in more detail when, at the end of life, 26 patients (52%) were terminally transferred to continuous medication administered subcutaneously. Continuous subcutaneous linear driver for analgosedation containing two components was used in 12 patients (46.2%) or three components in 14 patients (53.8%).

Conclusions: This retrospective study highlights the importance of targeted pharmacotherapy adjustments in terminal care, including multidisciplinary HHC teams. Pharmacotherapy is simplified and targeted to prevalent symptoms, using the widely used subcutaneous drug administration.

在家庭安宁疗护的生命最后几天药物治疗的调整:一项试点回顾性研究。
背景:有效的临终关怀需要药物治疗从慢性疾病管理过渡到症状缓解。临终前和晚期姑息治疗的患者可能有可能在适应症、剂量、给药途径和多种药物方面接受不适当的药物,这可能增加生活质量恶化的风险。然而,这一过程的数据在家庭临终关怀(HHC)是有限的。这项前瞻性回顾性研究评估了50例HHC患者在其最后几天的药物治疗,重点关注治疗的变化和首选给药途径,以优化症状护理。方法:回顾性分析匿名医疗记录数据,以评估从慢性病药物治疗转向以症状和生活质量为重点的治疗。采用统计方法确定药物利用和给药途径的趋势。结果:研究组确定了与潜在药物相关问题相关的最常见药物:抗抑郁药(26%)、镇静剂/催眠药(32%)、胃保护药(34%)、抗高血压药(46%)、共镇痛药(50%)和镇痛药(84%)。在最后一天,平均为2.64次全身用药(标准差1.27),药物最少,最多6次。最常见的症状是疼痛,该组中有28例(56%)患者出现疼痛。因此,在生命结束时,26例(52%)患者被转移到持续皮下给药时,晚期镇痛镇静被更详细地描绘出来。12例患者(46.2%)或14例患者(53.8%)使用含两种成分的连续皮下线性驱动剂用于镇痛镇静。结论:这项回顾性研究强调了包括多学科HHC团队在内的终末期护理中靶向药物治疗调整的重要性。药物治疗是简化和针对普遍的症状,使用广泛使用的皮下给药。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Annals of palliative medicine
Annals of palliative medicine Medicine-Anesthesiology and Pain Medicine
自引率
0.00%
发文量
231
期刊介绍: Annals of Palliative Medicine (Ann Palliat Med; Print ISSN 2224-5820; Online ISSN 2224-5839) is an open access, international, peer-reviewed journal published quarterly with both online and printed copies since 2012. The aim of the journal is to provide up-to-date and cutting-edge information and professional support for health care providers in palliative medicine disciplines to improve the quality of life for patients and their families and caregivers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信